Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 10577.145 | 0.9652 | 0.9281 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 10577.145 | 0.9899 | 0.9792 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 10577.145 | 0.9853 | 0.9696 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 10577.145 | 1.0068 | 1.0140 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 10577.145 | 1.0502 | 1.1039 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 10577.145 | 0.8606 | 0.7125 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 10577.145 | 0.6936 | 0.3704 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10577.145 | 0.6290 | 0.2386 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 10937.145 | 0.9329 | 0.8884 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 10937.145 | 0.9950 | 0.9917 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 10937.145 | 0.9525 | 0.9211 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 10937.145 | 0.9593 | 0.9324 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 10937.145 | 1.0397 | 1.0654 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 10937.145 | 0.9898 | 0.9832 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 10937.145 | 0.6533 | 0.4068 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 10937.145 | 0.0653 | -0.7904 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10937.145 | 0.0055 | -0.9728 | 1.2098 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000256 | uM | 10578.145 | 0.9638 | 0.9565 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00128 | uM | 10578.145 | 0.9523 | 0.9425 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0064 | uM | 10578.145 | 0.9727 | 0.9672 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.032 | uM | 10578.145 | 0.9490 | 0.9385 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 10578.145 | 0.9835 | 0.9803 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 10578.145 | 0.6110 | 0.4907 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 10578.145 | 0.0735 | -0.5785 | 1.6766 | |
| HCC38 | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 10578.145 | 0.0348 | -0.7303 | 1.6766 |